Stock MIRM MIRUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Market Closed - Nasdaq
Other stock markets
 03:59:48 2024-06-04 pm EDT 		5-day change 1st Jan Change
25.79 USD +1.74% Intraday chart for Mirum Pharmaceuticals, Inc. +4.16% -12.64%
May. 31 Mirum Pharmaceuticals Gets Positive Opinion From EU Committee on Marketing Authorization for Livmarli to Treat PFIC MT
May. 31 Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Mirum Pharmaceuticals: positive CHMP-Stellungnahme für LIVMARLI® (Maralixibat) als orale Lösung zur Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten
Mirum Pharmaceuticals Gets Positive Opinion From EU Committee on Marketing Authorization for Livmarli to Treat PFIC
Mirum Pharmaceuticals Announces Positive Chmp Opinion for Livmarli® (Maralixibat) Oral Solution for the Treatment of Pfic in Patients Three Months of Age and Older
Mirum Pharmaceuticals, Inc. Reiterates Revenue Guidance for the Year 2024
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Mirum Pharmaceuticals, Inc Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
LIVMARLI (solution orale de maralixibat) de Mirum Pharmaceuticals reçoit une recommandation de remboursement positive de l’ACMTS du Canada pour le traitement du prurit cholestatique chez les patients atteints du syndrome d’Alagille
Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Sector Update: Health Care
US FDA approves expanded use of Mirum's liver disease drug
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis
Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Mirum Pharmaceuticals, Inc. Announces Management Changes
Mirum Pharmaceuticals Names Joanne Quan as Chief Medical Officer
Mirum Pharmaceuticals, Inc. Announces Management Appointments
Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023
Sector Update: Health Care Stocks Rise in Late Afternoon
Sector Update: Health Care Stocks Rising Monday Afternoon
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRM Stock
  4. News Mirum Pharmaceuticals, Inc.
  5. Other languages